GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ContraFect Corp (OTCPK:CFRXQ) » Definitions » Shiller PE Ratio

ContraFect (ContraFect) Shiller PE Ratio : (As of Jun. 01, 2024)


View and export this data going back to 2014. Start your Free Trial

What is ContraFect Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


ContraFect Shiller PE Ratio Historical Data

The historical data trend for ContraFect's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ContraFect Shiller PE Ratio Chart

ContraFect Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ContraFect Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ContraFect's Shiller PE Ratio

For the Biotechnology subindustry, ContraFect's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ContraFect's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ContraFect's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ContraFect's Shiller PE Ratio falls into.



ContraFect Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

ContraFect's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, ContraFect's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.5/129.8595*129.8595
=-0.500

Current CPI (Sep. 2023) = 129.8595.

ContraFect Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 -817.235 98.326 -1,079.326
201403 -389.714 99.695 -507.631
201406 -342.813 100.560 -442.698
201409 -976.000 100.428 -1,262.030
201412 -187.435 99.070 -245.688
201503 -192.000 99.621 -250.279
201506 -264.000 100.684 -340.500
201509 -176.000 100.392 -227.661
201512 -224.000 99.792 -291.490
201603 -256.000 100.470 -330.884
201606 -280.000 101.688 -357.570
201609 -224.000 101.861 -285.571
201612 72.000 101.863 91.789
201703 -120.000 102.862 -151.495
201706 -56.000 103.349 -70.365
201709 -16.000 104.136 -19.952
201712 -48.000 104.011 -59.929
201803 -208.000 105.290 -256.538
201806 -216.000 106.317 -263.831
201809 -48.000 106.507 -58.525
201812 56.000 105.998 68.606
201903 116.800 107.251 141.422
201906 -87.200 108.070 -104.782
201909 -53.600 108.329 -64.253
201912 -88.800 108.420 -106.360
202003 -39.200 108.902 -46.744
202006 -70.400 108.767 -84.052
202009 -15.200 109.815 -17.974
202012 -18.400 109.897 -21.742
202103 -14.400 111.754 -16.733
202106 -11.200 114.631 -12.688
202109 -10.400 115.734 -11.669
202112 -8.800 117.630 -9.715
202203 -41.000 121.301 -43.893
202206 -36.790 125.017 -38.215
202209 -34.720 125.227 -36.005
202212 -16.140 125.222 -16.738
202303 -0.690 127.348 -0.704
202306 -1.940 128.729 -1.957
202309 -0.500 129.860 -0.500

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ContraFect  (OTCPK:CFRXQ) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


ContraFect Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of ContraFect's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ContraFect (ContraFect) Business Description

Traded in Other Exchanges
N/A
Address
28 Wells Avenue, 3rd Floor, Yonkers, NY, USA, 10701
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.
Executives
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Lishan Aklog director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Michael Messinger officer: VP Finance 238 PENNINGTON HARBURTON ROAD, PENNINGTON NJ 08534
Cary Sucoff director 1612 EAST CAPE CORAL PKWY, C/O LEGACY EDUCATION ALLIANCE, INC., CAPE CORAL FL 33904
David N. Low director EMBARCADERO FOUR, SUITE 650, SAN FRANCISCO CA 94111
Sol J Barer director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Lisa Ricciardi director C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Joshua B Muntner officer: SVP Business Development 30 FIFTH AVENUE, 12F, NEW YORK NY 10011
Shanghai Fosun Pharmaceutical (group) Co., Ltd. 10 percent owner BUILDING A, NO. 1289 YISHAN ROAD, SHANGHAI F4 200233
Fosun Industrial Co., Ltd 10 percent owner FLAT/ROOM 808, ICBC TOWER, 3 GARDEN ROAD, HONG KONG F4 00000
Cara M Cassino officer: Chief Medical Officer 757 STONY POINT ROAD, BENSON VT 05743
Natalie Bogdanos officer: General Counsel 207-23 DARREN DRIVE, BAYSIDE NY 11360
Roger Pomerantz director 711 HARVEST HILL ROAD, CHALFONT PA 18914
Michael J. Otto director 303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421

ContraFect (ContraFect) Headlines

From GuruFocus